Bayer to support Harvard Research Study to evaluate trust in science, including in COVID-19 pandemic

BayerWith the public debate on the merits of scientific data throughout the COVID-19 pandemic, Bayer announced its support for a new, multi-year Harvard Data Science Initiative (HDSI) research effort. This initiative will explore the public engagement with science, and better understand how to build confidence in the reliability, capability and integrity of scientific data and sound science.

"Scientific progress is essential to solve the pressing challenges of our time," said Werner Baumann, Chief Executive Officer at Bayer. "We are honored to join the Harvard Data Science Initiative’s efforts to evaluate the best ways to strengthen public dialogue around science and empower future evidence-based innovation. The acceptance of science is critical for human progress."

The HDSI Research Fund for Trust in Science supports the advancement of trust in science through data-driven, actionable insights. The first HDSI undertaking will be to study the public response to scientists and scientific findings in the wake of COVID-19, with other trust in science topics addressed in the future. These findings can guide future activities that strengthen the role of science and facts in decision making. Bayer has committed to support this multi-year research initiative with a total of one million US dollars.

"While scientists have emerged as visible advisors during the COVID-19 pandemic, a public debate has emerged about the value and validity of scientific research as nations evaluate the next steps in their recovery," said Monika Lessl, Head of Corporate R&D, Social Innovation at Bayer and Executive Director of the Bayer Foundation. "Therefore, we will work with the HDSI to evaluate the successes of and learnings from scientific communication during the pandemic's early months and identify opportunities to further improve the delivery of scientific data and insights among key audiences."

Established in 2017, the HDSI coalesces activity in statistics, computer science, and diverse fields of application to advance data science methodologies and apply them to questions of societal importance and impact. Through its Corporate Membership Program, the HDSI connects leading global organizations with Harvard’s broad data science ecosystem to create opportunities for long-term scientific, economic, and social progress. Bayer joined the program in January 2020.

"Public trust in science is fundamental to our ability to change the world for the better, whether in academia, government, non-profit or industry," said Francesca Dominici, co-Director of the HDSI and Clarence James Gamble Professor of Biostatistics, Population and Data Science at the Harvard T.H. Chan School of Public Health. "We are fortunate to have a partner like Bayer who is committed to thinking creatively and holistically about how data can illuminate the path toward a healthier future."

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros.

About Harvard Data Science Initiative

The Harvard Data Science Initiative was launched in 2017 to connect data science efforts across Harvard University's numerous schools and research centers. It combines and coordinates diverse technical and domain expertise to ignite moonshot initiatives and drive scientific, economic, and social progress. Through its research and education initiatives the HDSI revolutionizes and amplifies data-driven approaches to creating new knowledge for the world.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...